KLK3 and prostate carcinoma: 18F-fluciclovine (Axumin®; Blue Earth Diagnostics, Burlington, MA, USA), chemically abbreviated as 3-18FACBC, was approved by the FDA in May 2016 as a PET radiotracer for patients with suspected recurrence of prostate cancer based on elevated PSA levels following treatment [45].